Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Budesonide Inhaler Market Growth From $7.45 Billion In 2026 To $10.25 Billion By 2030 At A CAGR Of 8.3%
The budesonide inhaler market has experienced robust expansion over recent years. Projections indicate its size will increase from $6.88 billion in 2025 to $7.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.3%. The market’s past growth is attributable to factors such as the rising prevalence of asthma, increased rates of COPD diagnosis, the broader adoption of corticosteroid inhalers, an expansion in hospital respiratory care, and respiratory ailments associated with smoking.
The budesonide inhaler market is expected to experience substantial growth over the next few years. It is forecast to reach $10.25 billion by 2030, showing a compound annual growth rate (CAGR) of 8.3%. This projected expansion during the forecast period is propelled by the rising prevalence of chronic respiratory diseases, the development of smart inhalers, an increase in outpatient respiratory care, a focus on preventive asthma management, and demand from developing markets. Key developments anticipated for this period include a growing need for long-term respiratory management, wider adoption of combination inhalers, expansion in homecare respiratory solutions, increased usage in pediatric and geriatric populations, and a dedicated effort towards improving inhaler delivery effectiveness.
Get A Free Sample Report With In-Depth Market Insights:
Budesonide Inhaler Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The future expansion of the budesonide inhaler market is anticipated to be significantly propelled by the increasing incidence of respiratory ailments. These medical conditions, which impact the lungs and airways, lead to breathing difficulties and frequently manifest through symptoms such as coughing, wheezing, and breathlessness. Key examples encompass asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and various lung infections. A primary contributor to the escalation of these disorders is the growing air pollution, which heightens exposure to irritants that inflame airways and impair lung function. Budesonide inhalers play a crucial role in managing respiratory issues by directly administering anti-inflammatory medication to the lungs, thereby ensuring sustained control. Their convenient, portable design facilitates ease of use and transport, helping to minimize acute exacerbations and enhance overall respiratory well-being. Illustratively, Public Health Wales, a UK-based National Health Service organization in Wales, indicated in June 2025 that the population of patients registered with asthma and chronic obstructive pulmonary disease in Wales is expected to climb over the ensuing 10 years. Specifically, asthma cases are predicted to rise to over 256,000 from 237,400 in 2023-24, while chronic obstructive pulmonary disease cases are projected to reach over 84,000 from 75,600 in 2023-24. Consequently, the expanding prevalence of respiratory conditions is fueling the growth of the budesonide inhaler market.
Budesonide Inhaler Market Segment Analysis And Revenue Potential
The budesonide inhaler market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers
2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis
4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies
Subsegments:
1) By Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers
3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers
4) By Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers
Budesonide Inhaler Market Innovation Trends Shaping Future Development
Major companies engaged in the budesonide inhaler market are prioritizing the creation of innovative products, particularly generic versions, to boost affordability and broaden access to treatments for respiratory ailments. Generic inhalation products are non-branded forms of inhaled medications that deliver the identical active ingredients, dosage, and therapeutic effects as their branded counterparts, usually at a lower price. For example, in July 2023, Viatris Inc., a US-based pharmaceutical company, in partnership with Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, introduced Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, which is the first Food and Drug Administration (FDA)-approved generic version of Symbicort. This drug-device combination is formulated to manage asthma and chronic obstructive pulmonary disease (COPD), operating by reducing airway inflammation with budesonide and relaxing muscles around the airways with formoterol, thereby presenting patients with a more economical choice.
Budesonide Inhaler Market Key Players Shaping Industry Direction
Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.
View The Full Budesonide Inhaler Market Report:
Budesonide Inhaler Market Regional Analysis And Top Geography
North America was the largest region in the budesonide inhaler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model